Literature DB >> 10667898

Seronegative HIV-2 carriers in India.

S Kageyama1, J K Maniar, M Iwasaki, J Zhang, D G Saple, H Tsuchie, A Tanabe-Tochikura, K Taniguchi, K Shiraki, T Kurimura.   

Abstract

The discordant cases of seronegative, but culture and proviral HIV-2 DNA positive were found in Mumbai, India. This was corroborated by the successful isolation of HIV-2-RNA in culture medium, HIV-2 cDNA sequence determination and the detection of the antigen. The sequence of the isolated HIV-2 genomic RNA does not seem to be altered to the extent that the change will alter antibody binding. Furthermore, antibody from the same individual (even at 8 months from initial sampling) from whom HIV-2 was isolated did not react with the antigen of this strain. Those evidences imply that extremely low or non-production of the antibody may be due to suboptimal immune stimulation due to extremely slow HIV-2 replication. This low virus-load may be responsible for the negative antibody results in the HIV-2 carriers.

Entities:  

Keywords:  Antibodies; Antigens; Asia; Biology; Clinical Research; Developing Countries; Diseases; Examinations And Diagnoses; Hiv Infections; Hiv Serodiagnosis; Immunity; Immunologic Factors; India; Laboratory Examinations And Diagnoses; Physiology; Research Methodology; Research Report; Southern Asia; Viral Diseases

Mesh:

Substances:

Year:  2000        PMID: 10667898     DOI: 10.1258/0956462001914878

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

1.  Introduction of human immunodeficiency virus type 2 infection in the Philippines.

Authors:  Prisca Susan Leaño; Seiji Kageyama; Adelfa Espantaleon; Janak Maniar; Masaomi Iwasaki; Dattatray Saple; Namiko Yoshihara; Takashi Kurimura; Dorothy May Agdamag
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

2.  HIV-1/2 differentiation in a South African public laboratory.

Authors:  Rendani T Mafuyeka; Lynne M Webber; Piet Becker; Simnikiwe H Mayaphi
Journal:  South Afr J HIV Med       Date:  2021-03-12       Impact factor: 2.744

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.